AR054444A2 - Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante - Google Patents

Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Info

Publication number
AR054444A2
AR054444A2 ARP060101807A ARP060101807A AR054444A2 AR 054444 A2 AR054444 A2 AR 054444A2 AR P060101807 A ARP060101807 A AR P060101807A AR P060101807 A ARP060101807 A AR P060101807A AR 054444 A2 AR054444 A2 AR 054444A2
Authority
AR
Argentina
Prior art keywords
rapamycin
antioxidant
derivative
solid form
weight
Prior art date
Application number
ARP060101807A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054444(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR054444A2 publication Critical patent/AR054444A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Una mezcla en forma solida comprende una rapamicina o un derivado de rapamicina que tiene propiedades inmunosupresoras y un antioxidante, donde el antioxidante está presente en una cantidad de desde más del 0 al 1% en base al peso de la rapamicina o del derivado de rapamicina.
ARP060101807A 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante AR054444A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
AR054444A2 true AR054444A2 (es) 2007-06-27

Family

ID=26314797

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene

Country Status (38)

Country Link
US (5) US6605613B2 (es)
EP (4) EP1137439B2 (es)
JP (3) JP3805625B2 (es)
KR (2) KR20060096477A (es)
CN (2) CN1261163C (es)
AR (3) AR026102A1 (es)
AT (1) ATE365051T1 (es)
AU (1) AU759219B2 (es)
BE (1) BE1012869A3 (es)
BR (1) BR9915986A (es)
CA (3) CA2651609A1 (es)
CO (1) CO4980847A1 (es)
CY (1) CY1106870T1 (es)
CZ (2) CZ303006B6 (es)
DE (1) DE69936352T3 (es)
DK (1) DK1137439T4 (es)
ES (1) ES2288033T5 (es)
FR (1) FR2786771B1 (es)
GB (2) GB9826882D0 (es)
HK (1) HK1038889B (es)
HU (2) HU230174B1 (es)
ID (1) ID29250A (es)
IL (1) IL143092A0 (es)
IT (1) IT1319701B1 (es)
MY (2) MY127579A (es)
NO (2) NO332698B1 (es)
NZ (2) NZ511936A (es)
PE (1) PE20001333A1 (es)
PL (2) PL208854B1 (es)
PT (1) PT1137439E (es)
RU (1) RU2243769C2 (es)
SG (1) SG151072A1 (es)
SI (1) SI1137439T2 (es)
SK (2) SK287325B6 (es)
TR (2) TR200201428T2 (es)
TW (2) TWI248938B (es)
WO (1) WO2000033878A2 (es)
ZA (1) ZA200104360B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
WO2003068980A2 (en) 2002-02-13 2003-08-21 Biogal Gyogyszergyar Rt Method for extracting a macrolide from biomatter
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
TR200500302T3 (tr) 2003-03-31 2005-04-21 Biogal Gyogyszergyar Rt. Makrolidlerin kristalizasyonu ve saflaştırılması.
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
ATE378345T1 (de) 2003-07-24 2007-11-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur aufreinigung von makroliden
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005056103A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
CN101076319A (zh) * 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
AR058283A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
AU2006331874A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
KR20140093764A (ko) * 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
CN103127100A (zh) 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
CA2797501A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
CN103140494A (zh) * 2010-08-04 2013-06-05 美利奴生命科学有限公司 制备具有抗增殖特性的新的42-o-(杂烷氧基烷基)雷帕霉素化合物的方法
WO2012066502A1 (en) 2010-11-19 2012-05-24 Biocon Limited Processes for preparation of everolimus and intermediates thereof
EP2717884A1 (en) 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (es) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道(菏泽)制药有限公司 一种晶体形式的依维莫司及其制备方法
US10383860B2 (en) 2015-07-28 2019-08-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
EP3342410A4 (en) * 2015-08-28 2019-04-24 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION WITH RAPAMYCIN OR DERIVATIVES THEREOF
JP7020914B2 (ja) * 2015-09-18 2022-02-16 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
EP3466424A1 (en) 2016-05-27 2019-04-10 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprizing rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
JP2023519875A (ja) 2020-03-27 2023-05-15 ボストン サイエンティフィック サイムド,インコーポレイテッド 薬品の結晶化のための方法
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
JPH01249651A (ja) 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク/蒸留可能な結合剤組成物
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) * 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
DK0593227T3 (da) 1992-10-13 2006-05-01 Wyeth Corp Carbamater af rapamycin
KR100400620B1 (ko) * 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
NZ333657A (en) * 1996-07-30 2000-05-26 Novartis Ag A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
EP0975330A1 (en) 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
KR20060096477A (ko) 2006-09-11
HU230174B1 (hu) 2015-09-28
CZ303006B6 (cs) 2012-02-22
DE69936352D1 (de) 2007-08-02
US7297703B2 (en) 2007-11-20
ATE365051T1 (de) 2007-07-15
TR200201428T2 (tr) 2002-12-23
US20020032213A1 (en) 2002-03-14
PL208854B1 (pl) 2011-06-30
SG151072A1 (en) 2009-06-29
RU2243769C2 (ru) 2005-01-10
EP1137439A2 (en) 2001-10-04
TR200101416T2 (tr) 2002-01-21
ID29250A (id) 2001-08-16
US7572804B2 (en) 2009-08-11
GB9904934D0 (en) 1999-04-28
CZ302210B6 (cs) 2010-12-22
IT1319701B1 (it) 2003-10-27
TWI270550B (en) 2007-01-11
EP2279751A2 (en) 2011-02-02
ES2288033T5 (es) 2012-04-10
EP2269651A2 (en) 2011-01-05
SK7662001A3 (en) 2001-12-03
HUP0104489A2 (hu) 2002-03-28
NO332698B1 (no) 2012-12-10
NO20012424D0 (no) 2001-05-16
SI1137439T1 (sl) 2008-06-30
CA2351580A1 (en) 2000-06-15
WO2000033878A3 (en) 2000-11-02
SI1137439T2 (sl) 2012-05-31
FR2786771B1 (fr) 2002-12-27
EP2269651A3 (en) 2011-03-09
EP2279751A3 (en) 2011-02-16
CA2351580C (en) 2012-03-20
US20090270441A1 (en) 2009-10-29
KR20010101128A (ko) 2001-11-14
DE69936352T2 (de) 2008-02-14
HU228939B1 (en) 2013-07-29
JP2002531527A (ja) 2002-09-24
US6852729B2 (en) 2005-02-08
US6605613B2 (en) 2003-08-12
SK286688B6 (sk) 2009-03-05
JP2006111637A (ja) 2006-04-27
EP1743657A2 (en) 2007-01-17
JP2005200429A (ja) 2005-07-28
BR9915986A (pt) 2001-09-04
JP3805625B2 (ja) 2006-08-02
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
CN1374872A (zh) 2002-10-16
CN1876657B (zh) 2013-01-09
SK287325B6 (sk) 2010-07-07
AR048073A2 (es) 2006-03-29
HUP0104489A3 (en) 2004-05-28
HK1038889B (zh) 2008-01-25
AR026102A1 (es) 2003-01-29
JP5165199B2 (ja) 2013-03-21
ITMI992520A1 (it) 2001-06-02
US20080161334A1 (en) 2008-07-03
CZ20012001A3 (cs) 2001-09-12
AU1657300A (en) 2000-06-26
CA2732620A1 (en) 2000-06-15
PE20001333A1 (es) 2000-12-12
ES2288033T3 (es) 2007-12-16
KR100695834B1 (ko) 2007-03-19
NO20121113L (no) 2001-05-16
GB9826882D0 (en) 1999-01-27
NO20012424L (no) 2001-05-16
US20030191148A1 (en) 2003-10-09
DK1137439T4 (da) 2012-03-19
NZ527781A (en) 2004-11-26
EP1137439B1 (en) 2007-06-20
CN1261163C (zh) 2006-06-28
FR2786771A1 (fr) 2000-06-09
EP1743657A3 (en) 2007-03-28
PL196627B1 (pl) 2008-01-31
TWI248938B (en) 2006-02-11
AU759219B2 (en) 2003-04-10
NO334612B1 (no) 2014-04-22
HK1038889A1 (en) 2002-04-04
CA2732620C (en) 2013-08-06
PT1137439E (pt) 2007-09-25
MY120594A (en) 2005-11-30
NZ511936A (en) 2003-10-31
CA2651609A1 (en) 2000-06-15
US20050107418A1 (en) 2005-05-19
WO2000033878A2 (en) 2000-06-15
BE1012869A3 (fr) 2001-04-03
EP1137439B2 (en) 2011-11-23
MY127579A (en) 2006-12-29
US7741338B2 (en) 2010-06-22
CN1876657A (zh) 2006-12-13
JP5043308B2 (ja) 2012-10-10
ITMI992520A0 (it) 1999-12-02
TW200540179A (en) 2005-12-16
IL143092A0 (en) 2002-04-21
CO4980847A1 (es) 2000-11-27
DE69936352T3 (de) 2012-05-03
ZA200104360B (en) 2002-01-16
PL348333A1 (en) 2002-05-20

Similar Documents

Publication Publication Date Title
AR054444A2 (es) Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante
SV2004001474A (es) Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido ref. pc23278
ES2195970T3 (es) L-ribavirina y usos de la misma.
TR201908551T4 (tr) Yakıt bileşimleri.
BR0312116A (pt) Artigo
AR030724A1 (es) Un metodo para formar articulos termoendurecidos reforzados y los articulos termoendurecidos reforzados producidos por el mismo
DK0679154T3 (da) Ny krystallinsk form af en d-vitamininanalog
ES2080134T3 (es) Compuestos fotocromicos de tipo indolino-espiro-oxazina, su procedimiento de preparacion, composiciones y articulos fotocromicos que contienen dichos compuestos.
AR034737A1 (es) Conjunto de elementos de desgaste
MY122619A (en) Ethylene/a-olefin copolymer, method for producing the same, and use thereof
ES2148120T3 (es) Metodo para la preparacion de citalopram.
GT200100008A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
AR004786A1 (es) Un procedimiento para la preparación de una composicion asfaltica de grado denso con un volumen total de huecos no mayor que el 10% y uso de la misma para aplicaciones en caminos
CY1105366T1 (el) Ανθελμινθικες συνθεσεις
UY27067A1 (es) Pirrolo (2.-a) dihidroisoquinolinas
ES2166504T3 (es) Compuestos de nitrogeno acilados que pueden ser utilizados como aditivos para un aceite lubricante y en composiciones combustibles.
ATE247617T1 (de) Entzendungshemmende antibakterielle benzylphenolverbindungen
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR023690A1 (es) Combinaciones de espesadores asociativos y composiciones acuosas para revestimientos protectores, uso de las mismas y producto revestido con dichacomposicion
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
ES2062294T5 (es) Uso de un aditivo como detergente, dispersante y antioxidante para combustibles y aceites lubricantes.
DE59610330D1 (de) Trockenlaufdichtungsring
AR043869A1 (es) Un producto alimenticio que comprende almidon y es ambientalmente estable
ES2082424T3 (es) 1-aminonaftalenos sustituidos y composiciones estabilizadas.
EA200400211A1 (ru) Лиофилизованная композиция 2-метилтиенобензодиазепина

Legal Events

Date Code Title Description
FG Grant, registration